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ABSTRACT
Therapy with interferon and ribavirin for hepatitis C virus (HCV) infection induces a decrease in
several haematological population counts. It is unclear whether haematological toxicity is more
severe in patients co-infected with HCV and human immunodeficiency virus (HIV). This study
analysed the evolution of haematological population counts during and after interferon and ribavirin
therapy for chronic HCV infection. Eleven patients co-infected with HIV and HCV and treated with
pegylated interferon plus ribavirin, and ten treated with standard interferon plus ribavirin, were
analysed. With reference to baseline values, neutrophil counts decreased by an average of 45%
(range 18–67%), total lymphocytes by 50% (16–63%), CD4 lymphocytes by 54% (16–61%),
haemoglobin by 9% (5–16%) and platelets by 31% (16–45%). The nadir of the decrease was
reached in the first weeks of therapy and was maintained while patients were receiving treatment.
The reduction in all series was higher with pegylated interferon. Patients recovered their baseline
counts after finishing the treatment. No cases of haemorrhage or outstanding infection were detected
during follow-up.
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INTRODUCTION
The increase in the survival of human immuno-
deficiency virus (HIV)-infected patients, related to
highly active anti-retroviral therapy (HAART) [1],
has been associated with higher morbidity and
mortality attributed to chronic hepatitis C virus
(HCV) infection [2]. HCV-induced liver disease
shows an accelerated course in patients co-infec-
ted with HIV [3–6]. Treatment of HCV infection
with interferon-a (IFN-a) and ribavirin can lead to
sustained eradication of the virus, which is
associated with a long-term improvement in liver
histology and, probably, with a reduction in the
risk of cirrhosis [7,8].
Treatment with IFN and ribavirin is not with-
out shortcomings. A common side-effect is bone
marrow suppression [9]. With the doses of IFN
required to treat hepatitis C, neutrophil and
lymphocyte counts can fall to levels associated
with an increase in the risk of opportunistic
infections [10]. This potential fall was not usually
associated with infection in a recent series of non-
HIV-infected patients receiving therapy against
HCV-related chronic hepatitis [11]. However,
although studies are currently underway, the risk
in HIV-co-infected patients has not yet been
evaluated properly [12–16]. Moreover, the combi-
nation with ribavirin, apart from increasing the
risk of anaemia, can reinforce the neutropenia
produced by IFN [7–10,17].
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In order to evaluate the haematological toxici-
ties of IFN (both pegylated and standard) plus
ribavirin in the treatment of chronic HCV infection
in HIV-co-infected patients, the present study
analysed prospectively the evolution of the differ-
ent haematological populations during and after
this therapy, as well as the incidence of opportun-
istic infections and haemorrhagic complications.
PATIENTS AND METHODS
Study population
This was a prospective study of 21 patients in the Hospital
Universitario Puerta del Mar (Cadiz, Spain) who were
co-infected with HIV and HCV. This tertiary hospital serves
a population of 270 000 inhabitants. The cumulative preval-
ence of AIDS in this area is 570 ⁄million inhabitants. Patients
were selected from those individuals who attended the
Infectious Disease Unit. Inclusion criteria were:
1. HIV infection, detected by the presence of anti-HIV
antibodies or by identification of HIV RNA. All patients
received HAART for ‡ 6 months; in 16 patients there was
an undetectable virus load (< 50 copies ⁄mL), while the
remainder had a virus load of < 5000 copies ⁄mL. CD4+
T-cell counts were > 250 ⁄ lL and no active opportunistic
disease was present. Indications for HAART were based
on each individual’s clinical, immunological and virologi-
cal status, according to the recommendations of the
International AIDS Society [18].
2. HCV co-infection, defined as a positive serological result
with a second- or third-generation enzyme-linked immu-
nosorbent assay and the detection of HCV RNA. A
maintained increase of serum aminotransferase levels for
‡ 6 months was required. All patients had undergone an
interpretable liver biopsy in the previous 6 months; a
minimum fibrosis score of ‡ 1, according to the histological
index proposed by Knodell and modified by Scheuer and
Desmet [19], was the indication for therapy.
Exclusion criteria were as follows: (1) clinical or biochemical
criteria of decompensated cirrhosis; (2) positive hepatitis B
surface antigen; (3) other infectious, autoimmune, tumoural,
biliary or vascular-associated liver disease; (4) active alcohol or
drug dependence; (5) a Karnofsky index of < 80; (6) absolute
neutrophil counts of < 1500 cells ⁄ lL, a platelet count of
< 90 000 cells ⁄ lL or a haemoglobin concentration of
< 11.0 g ⁄dL; (7) poorly controlled psychiatric disease; (8)
substantial coexisting medical conditions; (9) inability to use
contraceptive measures, for any reason; and (10) previous IFN
or ribavirin therapy.
The study protocol was approved by the Institutional
Ethical Committee, and all patients and controls gave their
informed consent.
Study design
Eleven patients were selected at random to receive treatment
with pegylated IFN-a-2a (PEG-IFN, Pegasys; Hoffman-La
Roche, Nutley, NJ, USA) at a dose of 180 lg subcutaneously
each week, plus ribavirin. Another ten patients received
treatment with IFN-a-2a (standard IFN) (Roferon-A; Hoff-
man-La Roche) at a dose of 3 million units three times
weekly, plus ribavirin. The daily dose of ribavirin for patients
in both groups was 800 mg. Treatment was continued for
48 weeks.
All patients were followed in a similar way, with a visit for
selection during the 35 days before the start of treatment. At
this initial visit, a detailed clinical history was taken, with
haematogram and differential counts, coagulation and routine
biochemical tests, thyrotropin and anti-thyroid antibody
measurements, an elemental study of urine, thorax radiogra-
phy, abdominal ultrasonography, and determination of HCV
genotype, HCV and HIV virus loads, and CD4+ T-cell counts.
Once the patient had been selected, clinical and analytical
evaluations were performed in weeks 0, 2, 4, 6, 8, 12, 24, 48 and
72. In each of these evaluations, the results of anamnesis and
physical examination, complete blood counts, CD4+ T-cell
counts, and routine liver and renal tests, were recorded.
Determinations of HIV RNA and HCV RNA load were
performed at 4, 12, 24, 48 and 72 weeks.
Side-effects and toxicity of therapy were classified accord-
ing to the usual criteria [20]. Dose adjustments following
changes in neutrophil, haemoglobin and platelet counts are
reported in Table 1. Colony-stimulating factors were not
administered. Co-trimoxazole prophylaxis was given to
patients with < 200 CD4+ T-cells ⁄lL during the follow-up.
Criteria for interruption of the study were: (1) appearance
of an opportunistic infection; (2) concurrent disease that
required the use of immunosuppressive therapy; (3) virologi-
cal failure in the control of HIV infection; (4) decision of the
patient not to continue the treatment; or (5) positive HCV RNA
after treatment for 24 weeks in those patients who received
standard IFN plus ribavirin.
Laboratory determinations
Automated tests were used for the haematogram, routine
biochemistry, coagulation and the elemental study of urine.
Serum reactivity for anti-HIV was determined by enzyme
immunoassay (EIA; Abbott Laboratories, North Chicago, IL,
USA) and confirmed with Western blot (Pasteur Institute,
Paris, France). CD4 cell counts were determined by standard
flow cytofluorometry. Plasma HIV load was determined by
RT-PCR (Amplicor HIV; Roche Diagnostics, Basel, Switzer-
land), with a sensitivity of 50 RNA copies ⁄mL of plasma.
Sera from all subjects were reactive for anti-HCV by both a
second-generation EIA (EIA-2; Ortho Diagnostic System,
Raritan, NJ, USA) and a second-generation recombinant
immunoblot assay (RIBA-2; Ortho Diagnostic System). Plasma
samples were tested for HCV RNA by RT-PCR (Amplicor
HCV; Roche Diagnostics). When values exceeded the range of
the assay, plasma samples were diluted and determinations
were repeated. HCV genotypes were determined by line probe
assay (INNO-LiPA HCV; Innogenetics, Antwerp, Belgium) as
described previously [21].
Graduation of necroinflammatory activity and the fibrosis
stage of liver biopsies was performed with the index of
histological activity proposed by Knodell, modified by Desmet
et al. [19].
Statistical analysis
Quantitative variables are presented as means ± standard
deviations if they followed a normal distribution, according
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to the Shapiro–Wilk test, or as median values with 95%
confidence intervals (95% CI). Qualitative variables are
presented as absolute numbers and percentages. Data from
two independent groups were compared with the Mann–
Whitney U-test. The significance of parameters within each
group was tested with the Wilcoxon matched-pairs signed-
rank test. For qualitative variables, the chi-square test with
Yates’ correction or Fisher’s exact test was used. A p value of
< 0.05 was considered significant. Statistical analyses were
performed with SSPS v.11.0 software (SPSS Inc., Chicago, IL,
USA).
RESULTS
Twenty-one patients were included in the treat-
ment protocol. The baseline characteristics of
individuals are shown in Table 2. There was
no significant difference between the standard
IFN and PEG-IFN groups with respect to
baseline demographics, or histological or viro-
logical characteristics. Likewise, anti-retroviral
therapy was similar in both groups (data not
shown).
A maintained virus response (negative for HCV
RNA at 6 months after completion of therapy)
was observed for nine (42.9%) patients, of whom
seven were in the PEG-IFN group and two were
in the standard IFN group. Twelve (57.1%)
patients remained positive for HCV RNA. Of
these, five patients receiving standard IFN had a
detectable RNA virus load at week 24; treatment
was withdrawn from these patients. Two further
patients receiving PEG-IFN had a detectable virus
load at 48 weeks, and a third patient, with a
virological response at 48 weeks, subsequently
relapsed, with HCV RNA being detectable at
72 weeks. Therapy was suspended for the final
five patients because of adverse effects: one
cirrhotic patient in the standard IFN group had
a hydropic decompensation in week 8; a patient in
the PEG-IFN group presented with hyperthyroid-
ism in week 20; and the final two patients, one
from each treatment group, suffered a depression-
anxiety disorder, and asked for therapy to be
suspended (both in week 18).
Table 1. Dose adjustments for patients with diminution in
absolute neutrophil counts, haemoglobin levels or platelet
counts
Haematological
population
Adjustment of
dose of IFN
Number of patients
and treatment group,
where dose
adjustment
was necessary
Neutrophils (cells/lL)
‡1000 None
750–999 Weeks 1–2 25% reduction of dose
Weeks 3–48 None
500–749 Weeks 1–2 Interruption of treatment
until ‡750
2 patients
Weeks 3–48 25% reduction of
next dose only (PEG-IFN group)
25% reduction of dose
250–499 Weeks 1–2 Interruption of treatment
until ‡750
50% reduction of next
dose only
Weeks 3–48 Interruption of treatment
until ‡750
50% reduction of next
dose only
<250 Interruption of treatment
with PEG-IFN
Platelets (cells/lL)
‡50 000
<50 000–35 000
None
Interruption of treatment
until ‡50 000
3 patients
(PEG-IFN group)
25% reduction of next
dose only
Interruption of treatment
until ‡50.000
<35 000–25 000 50% reduction of next
dose only
<25 000 Interruption of treatment
with PEG-IFN
The interferon (IFN) dose was not adjusted in response to haemoglobin
concentration. The ribavirin dose was reduced by 200 mg/day if the haemoglobin
concentration was >8.5 but <10 g/dL, and treatment was suspended if the
haemoglobin concentration was <8.5 g/dL.
Table 2. Baseline characteristics of patients co-infected
with human immunodeficiency virus (HIV) and hepatitis
C virus (HCV)
Parameter
Value
Overall
Standard
interferon
group
(n = 10)
Pegylated
interferon
group
(n = 11)
Age, years (range) 34 (33–39) 35 (33–37.5) 33 (32.5–40)
Males, n (%) 15 (71.4) 8 (80) 7 (63.6)
Duration of infection,
years (range)
16 (14–19) 14.5 (13–18.5) 16.5 (15.5–19)
Source of infection, n (%)
Parenteral drug use 16 (76.2) 8 (80) 8 (72.7)
Sexual contact 4 (19.2) 2 (20) 2 (18.2)
Transfusion 1 (4.8) 0 1 (9.1)
Genotype 1, n (%) 11 (52.8) 6 (60) 5 (45.4)
Fibrosis 2 (1–3) 2.5 (1–3) 2 (1–3)
Cirrhosis, n (%) 3 (14) 1 (10) 2 (18.2)
HCV virus load
(106 · IU ⁄mL)
2.06 (0.43–10.0) 1.02 (0.51–3.41) 5.56 (1.18–14.80)
HIV clinical stage, n (%)
A 14 (67) 6 (60) 8 (72.7)
B 3 (14) 1 (10) 2 (18.2)
C 4 (19) 3 (30) 1 (9.1)
Baseline CD4 T-cells ⁄ lL 592 (447–755) 655.75 (483–922.3) 554.4 (317.5–680.1)
Patients with baseline
CD4 T-cells > 500 ⁄ lL
12 (57.1) 6 (60) 6 (54.5)
Patients with HIV
load < 50 copies ⁄mL
16 (76.2) 8 (80) 8 (72.7)
Quantitative variables are expressed as medians (interquartile range). Data
correspond to the time when liver biopsy was performed.
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Changes in blood cell and platelet counts and
haemoglobin concentration during therapy
Baseline counts for neutrophils, total and CD4+
lymphocytes, and platelets, as well as haemoglo-
bin concentrations, are shown in Table 3. The
values of these parameters were similar (p > 0.05
in every case) in patients given PEG-IFN and in
those given standard IFN. In both groups of
patients, an early and maintained decrease in all
of the haematological series was observed (Ta-
ble 4). The largest decrease in neutrophil counts
was reached after therapy for 2 weeks with
standard IFN, and after 4 weeks in patients
receiving PEG-IFN. Two patients with neutrophil
counts of < 750 cells ⁄mL needed an adjustment of
their IFN dose (Table 1).
Fig. 1 shows the changes in white cell and
platelet counts and haemoglobin concentrations
over time. As the secondary effects resulting in
discontinuation of therapy presented at later
stages, data from the patients who discontinued
therapy are included. The lowest lymphocyte
count occurred at week 8 in patients receiving
standard IFN, and at week 12 in patients treated
with PEG-IFN. The lowest CD4 lymphocyte count
occurred at week 24 in patients receiving stand-
ard IFN, and at week 12 in patients treated with
PEG-IFN; however, the percentage of CD4+
T-cells in relation to the total lymphocyte count
was maintained during the entire follow-up
period. Six patients presented with CD4+ T-cell
values of < 200 ⁄mL; prophylaxis with co-trimoxa-
zole was initiated in these patients.
Platelet counts also diminished in the patients
studied. Those in the PEG-IFN group showed
larger and earlier decreases (week 4 of therapy)
than those in the standard IFN group (time until
nadir was 12 weeks). In three patients, the dose of
IFN was reduced following a platelet count of
< 50 000 cells ⁄mm3 (Table 1).
A slight decrease in haemoglobin concentra-
tions was also detected, with the lowest value
being reached at 12 weeks in the PEG-IFN group
and at 18 weeks in the standard IFN group.
Haemolytic anaemia was searched for and dis-
counted in all of the patients.
The dosages of PEG-IFN, standard IFN and
ribavirin were not related to the patients’ body
weights. A correlation of weight with the magni-
tude of the decrease in every item in the haem-
atological series was performed, but there were
no statistically significant correlations. Likewise,
in none of the haematological series was the
decrease associated with the presence or absence
of response to IFN plus ribavirin therapy (data
not shown).
Patients were placed into two function groups
according to whether their baseline values were
higher or lower than the median value of each
series. The percentage decrease was independent
of the baseline count (data not shown). Every
Table 3. Baseline neutrophil, total and CD4 lymphocyte
and platelet counts, and haemoglobin concentration
Haemotological series Treatment n Median Interquartile range
Neutrophils
(cells ⁄ lL)
Overall 21 2790 2260–3200
IFN 10 2375 2050–3985
PEG-IFN 11 2830 2780–3200
Total lymphocytes
(cells ⁄ lL)
Overall 21 2280 2080–2780
IFN 10 2250 2100–2995
PEG-IFN 11 2450 1700–2780
CD4 lymphocytes
(cells ⁄ lL) (% with
reference to total lymphocytes)
Overall 21 592 (24) 447–755 (20–34)
IFN 10 656 (26) 483–922 (22–36)
PEG-IFN 11 554 (23) 318–680 (18–33)
Platelets · 103
(cells ⁄ lL)
Overall 21 178 126–217
IFN 10 179 153–222
PEG-IFN 11 175 137–191
Haemoglobin
(g ⁄dL)
Overall 21 14.3 13.5–15.5
IFN 10 13.9 12.3–15.6
PEG-IFN 11 15.0 13.6–15.5
IFN, standard interferon + ribavirin group; PEG-IFN, pegylated interferon + rib-
avirin group.
Table 4. Comparison of the de-
crease in haematological parameters
from baseline until nadir, grouped
according to the type of interferonParameter
% decreasea Statistical significance of the
comparison of the decrease
between the groups of pegylated
and standard interferon (p)Overall
Pegylated
interferon
Standard
interferon
Neutrophil count 45 (18–67) 65 (56–77) 31 (2–49) 0.0001
Total lymphocyte
count
50 (16–63) 52 (44–57) 23 (1–43) 0.004
CD4+ T-lymphocyte
count
54 (16–61) 60 (52–61) 23 (5–41) 0.002
Platelet count 31 (16–45) 35 (23–51) 20 (7–27) 0.036
Haemoglobin
concentration
9 (5–16) 10 (8–21) 6 (1–12) 0.046
Values are given as medians (interquartile range) of the percentage of the decrease with reference to baseline.
aIn relation to baseline values.
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patient receiving PEG-IFN showed a decrease in
all levels analysed, with the exception of the
platelet count in two patients, which remained
stable. In the group of patients receiving standard
IFN therapy (n = 10), eight showed a decrease in
neutrophil count, seven in the total lymphocyte
count, nine in the CD4 lymphocyte count, nine in
the platelet count, and seven in the haemoglobin
concentration. Additionally, a larger median
decrease was observed in patients receiving
PEG-IFN in comparison with those receiving
standard IFN (Table 4).
Changes at follow-up
Twenty-four weeks after completing treatment,
either by premature retirement (virological fail-
ure, adverse effects) or by completion of therapy
for patients with virological response, patients
were re-evaluated. At this visit, median haema-
tological values had returned to their baseline
levels (Fig. 1). However, two patients still had a
CD4 T-cell count of < 200 ⁄lL; both were in the
PEG-IFN group.
None of the patients developed a haemorrhagic
complication or an opportunistic infection during
the follow-up. Likewise, the HIV viral load
remained undetectable in those patients where it
was undetectable at baseline, and remained at
similar levels (p > 0.05) in the remaining patients.
DISCUSSION
This study analysed the dynamics of haemato-
logical changes in HIV-infected patients receiving
treatment for chronic HCV infection. It was evi-
dent from the data that all parameters in the
haematological series decreased during treatment
with IFN and ribavirin. IFN is a bone marrow
depressor that inhibits the effects of several hae-
matopoietic growth factors. It inhibits production
of stimulating cytokines, such as granulocyte and
granulocyte–macrophage colony-stimulating fac-
tor, interleukin-1, interleukin-8 and interleukin-11,
and it increases the concentrations of inhibitors
(antagonistic receptor of interleukin-1) [22,23],
with all the haematopoietic series being affected
in different forms and degrees [24]. This suppres-
sion effect is dose-dependent [9,17]. The combina-
tion with ribavirin increases the risk of anaemia
and, probably, the risk of neutropenia [7,8,17]. The
effect on CD4+ T-cell counts has not been
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Fig. 1. Evolution of the median
neutrophil count (A), platelet count
(B), haemoglobin concentration (C),
total lymphocyte count (D) and CD4
lymphocyte count (E) in patients
with HIV–HCV co-infection receiv-
ing therapy with interferon plus
ribavirin. Values represent the med-
ian of the values attained at each
point of evolution. Continuous line,
overall group (n = 21); dashed line,
patients treated with pegylated
interferon (n = 11); dotted line,
patients treated with standard inter-
feron (n = 10).
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explained clearly, although the reduction in num-
bers of this lymphocyte subset has been linked to a
redistribution [25].
Descriptive analyses of haematological toxici-
ties have been performed in HCV-mono-infected
patients being treated for chronic hepatitis. A
reduction in white blood cell counts is the most
frequent haematological toxicity observed in
patients treated with IFN [7,8]. Fortunately, this
reduction in neutrophils has not been associated
with an increased risk of bacterial infection [11].
Indeed, in a pooled analysis of 2089 patients in the
pivotal studies of combination therapy for hepa-
titis C [26–28], neutropenia was not associated
with infection, with only one of 23 deaths repor-
ted from these studies being caused by infection.
An association between drug-induced neu-
tropenia and infection has been shown in chemo-
therapy studies, such as with oncology patients
undergoing therapy that severely suppresses the
immune system and bone marrow [29]. HIV-
infected patients have a high predisposition to
infectious diseases, mainly associated with a
lower CD4+ T-cell count. Thus, IFN-induced
decreases in neutrophil and lymphocyte counts
could be of greater relevance in this kind of
patient [30]. Consequently, therapy with IFN is
prescribed currently for HIV-infected patients
with a relatively intact immune system
[17,31,32]. The present data show that a 45%
decrease in neutrophil counts occurs in these
patients. This decrease implies the possibility of
severe neutropenia (< 750 cells ⁄mm3) in patients
who begin treatment with < 1500 neutro-
phils ⁄mm3, and the IFN doses were adjusted
because of low neutrophil counts in two patients
in the present series. However, as has been
demonstrated for non-HIV-infected patients
[11,21–23], these lower values were not associated
with an increase in severe bacterial infections
(those indicating hospital admission). Likewise,
an increase in opportunistic infections related to a
lower CD4+ T-cell count was not observed in
these patients. This is a remarkable situation
because, although a preserved CD4+ T-cell count
was present in this series of patients at the
beginning of the treatment, the magnitude of the
decrease in CD4 lymphocyte count (a median
decrease of 54%) could contribute to immuno-
suppression. Thrombocytopenia was also relat-
ively common in patients of this series, but
no severe haemorrhagic complications were
detected. Finally, the smallest reduction in the
haematological series was observed in haemoglo-
bin concentration. Evolution of red blood series is
of concern in HIV-infected patients because of the
influence in vitro of several nucleoside inhibitors
of reverse transcriptase on ribavirin concentra-
tions [33,34]. This was not a problem in the
present series, with haemoglobin values of
> 10 g ⁄dL being found during the entire follow-
up period in every patient.
One of the most interesting findings of this work
was the analysis of the dynamics of the haemato-
logical series. The nadir was detected at an early
stage (2–4 weeks in the case of neutrophils, and up
to 18 weeks in the case of lymphocytes). Remark-
ably, the reduction in haematological cell counts
persisted during the entire course of treatment.
Previously, a rebound in the levels of the blood
populations during the course of therapy has been
reported [25]. This was not the case in the present
series, although the curve for lymphocytes (total
and CD4) was complex (Fig. 1), because two
separate curves were superimposed, namely the
curve for patients treated with PEG-IFN, where a
continued decrease in lymphocyte numbers dur-
ing therapy was demonstrated, and the curve for
patients treated with standard IFN, where a
rebound can be seen after the first few weeks of
therapy. Recent results from a controlled trial of
therapy with PEG-IFN plus ribavirin in patients
co-infected with HIV and HCV also support the
maintenance of a decrease in the CD4+ T-cell count
during therapy [35].
Diminution seems to be a common phenom-
enon in patients treated with PEG-IFN: all the
cases receiving PEG-IFN in this study had signi-
ficant reductions in neutrophil and lymphocyte
counts and in haemoglobin concentration; in nine
of 11 patients, a significant and concomitant
diminution of platelet count was observed. Addi-
tionally, the decrease in patients receiving PEG-
IFN plus ribavirin was greater than that detected
in patients receiving standard IFN combined with
ribavirin. With a more extended use of PEG-IFN,
frequent dose adjustments may be required to
avoid these haematological toxicities. However, a
reduction in the amount of drug administered has
been linked with reduced effectiveness [36].
Alternatively, colony-stimulating factors, not
investigated in this study, could be used to allow
the full doses of IFN and ribavirin to be admin-
istered without severe haematological toxicity.
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Although no patients had severe opportunistic
infections or haemorrhagic complications during
this study (that is, the decrease in neutrophil and
lymphocyte counts could be interpreted as not
being excessively favourable to opportunistic
infections in HIV-infected patients treated with
IFN and ribavirin), caution must be exercised
because of the low number of patients. Studies
with larger patient series, currently under way,
will be needed to explore this topic.
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